CJ Bioscience, Inc. (KOSDAQ:311690)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,220
+140 (1.39%)
Last updated: Apr 28, 2025
-27.82%
Market Cap 133.92B
Revenue (ttm) 3.47B
Net Income (ttm) -32.84B
Shares Out 13.07M
EPS (ttm) -3,541.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,320
Average Volume 17,762
Open 10,180
Previous Close 10,080
Day's Range 10,080 - 10,350
52-Week Range 8,250 - 18,800
Beta 0.80
RSI 47.91
Earnings Date May 14, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 311690
Full Company Profile

Financial Performance

In 2024, CJ Bioscience's revenue was 3.47 billion, a decrease of -37.82% compared to the previous year's 5.58 billion. Losses were -32.84 billion, 43.3% more than in 2023.

Financial Statements

News

There is no news available yet.